Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy

Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy

Current treatment protocols have limited success against MYCN-amplified neuroblastoma. Adoptive T cell therapy presents an innovative strategy to improve cure rates. However, L1CAM-targeting CAR T cells achieved only limited response against refractory/relapsed neuroblastoma so far. We investigated...

Full description

Saved in:
Bibliographic Details
Main Authors: Laura Grunewald, Lena Andersch, Konstantin Helmsauer, Silke Schwiebert, Anika Klaus, Anton G. Henssen, Teresa Straka, Marco Lodrini, Sebastian G. Wicha, Steffen Fuchs, Falk Hertwig, Frank Westermann, Alice Vitali, Carlotta Caramel, Gabriele Büchel, Martin Eilers, Kathy Astrahantseff, Angelika Eggert, Uta E. Höpken, Johannes H. Schulte, Thomas Blankenstein, Kathleen Anders, Annette Künkele
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:Pharmacological Research
Subjects:
Adoptive T cell therapy
Childhood tumor
Combination therapy
MLN8237
MYCN-driven cancer
L1CAM-CAR T cells
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661825000337
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items